CCR Drug Updates: Sorafenib and Sunitinib in Renal Cell Carcinoma

This publication has 40 references indexed in Scilit:

• Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
  New England Journal of Medicine, 2007
• Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
  JNCI Journal of the National Cancer Institute, 2007
• Inhibition of Tumor Endothelial ERK Activation, Angiogenesis, and Tumor Growth by Sorafenib (BAY43-9006)
  The American Journal of Pathology, 2006
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
  Nature Reviews Drug Discovery, 2006
• Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
  European Journal Of Cancer, 2006
• Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells
  Journal of Biological Chemistry, 2003
• Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase
  Journal of Medicinal Chemistry, 2003
• Targeting RAS signalling pathways in cancer therapy
  Nature Reviews Cancer, 2003
• Role of transforming growth factor-alpha in von Hippel- Lindau (VHL)-/- clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
  Proceedings of the National Academy of Sciences, 2001
• Integrin αvβ3 Requirement for Sustained Mitogen-activated Protein Kinase Activity during Angiogenesis
  The Journal of cell biology, 1998